skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Barriers to effective TRAIL-targeted therapy of malignancy
Barriers to effective TRAIL-targeted therapy of malignancy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Barriers to effective TRAIL-targeted therapy of malignancy

Dyer, Martin J S ; MacFarlane, Marion ; Cohen, Gerald M

Journal of clinical oncology, 2007-10, Vol.25 (28), p.4505-4506 [Periódico revisado por pares]

United States

Sem texto completo

Citações Citado por
2
Spatial dynamics of TRAIL death receptors in cancer cells
Spatial dynamics of TRAIL death receptors in cancer cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

Spatial dynamics of TRAIL death receptors in cancer cells

Twomey, Julianne D ; Kim, Su-Ryun ; Zhao, Liqun ; Bozza, William P ; Zhang, Baolin

Drug resistance updates, 2015-03, Vol.19, p.13-21 [Periódico revisado por pares]

Scotland: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
Material Type:
Artigo 		Adicionar ao Meu Espaço

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response

López-Gómez, Carlos ; Oliver-Martos, Begoña ; Pinto-Medel, María-Jesús ; Suardiaz, Margarita ; Reyes-Garrido, Virginia ; Urbaneja, Patricia ; Fernández, Óscar ; Leyva, Laura

Journal of neurology, neurosurgery and psychiatry, 2016-02, Vol.87 (2), p.130-137 [Periódico revisado por pares]

England: BMJ Publishing Group

Texto completo disponível

Citações Citado por
4
A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells
A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells

Ivanov, Vladimir N. ; Hei, Tom K.

Apoptosis (London), 2014-03, Vol.19 (3), p.399-413 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por
5
Targeting the extrinsic apoptosis pathway in cancer
Targeting the extrinsic apoptosis pathway in cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Targeting the extrinsic apoptosis pathway in cancer

Ashkenazi, Avi

Cytokine & growth factor reviews, 2008-06, Vol.19 (3), p.325-331 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse
TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse
Material Type:
Artigo 		Adicionar ao Meu Espaço

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse

Bernardi, Stella ; Toffoli, Barbara ; Tisato, Veronica ; Bossi, Fleur ; Biffi, Stefania ; Lorenzon, Andrea ; Zauli, Giorgio ; Secchiero, Paola ; Fabris, Bruno

Clinical science (1979), 2018-01, Vol.132 (1), p.69-83 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
7
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
Material Type:
Artigo 		Adicionar ao Meu Espaço

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

Prabhu, Varun Vijay ; Morrow, Sara ; Rahman Kawakibi, Abed ; Zhou, Lanlan ; Ralff, Marie ; Ray, Jocelyn ; Jhaveri, Aakash ; Ferrarini, Isacco ; Lee, Young ; Parker, Cassandra ; Zhang, Yiqun ; Borsuk, Robyn ; Chang, Wen-I ; Honeyman, Joshua N. ; Tavora, Fabio ; Carneiro, Benedito ; Raufi, Alexander ; Huntington, Kelsey ; Carlsen, Lindsey ; Louie, Anna ; Safran, Howard ; Seyhan, Attila A. ; Tarapore, Rohinton S. ; Schalop, Lee ; Stogniew, Martin ; Allen, Joshua E. ; Oster, Wolfgang ; El-Deiry, Wafik S.

Neoplasia (New York, N.Y.), 2020-12, Vol.22 (12), p.725-744 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
8
A Phase 1b 2 trial of mapatumumab in patients with relapsed refractory non-Hodgkin's lymphoma
A Phase 1b 2 trial of mapatumumab in patients with relapsed refractory non-Hodgkin's lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase 1b 2 trial of mapatumumab in patients with relapsed refractory non-Hodgkin's lymphoma

Younes, A ; Vose, J M ; Zelenetz, A D ; Smith, M R ; Burris, H A ; Ansell, S M ; Klein, J ; Halpern, W ; Miceli, R ; Kumm, E ; Fox, N L ; Czuczman, M S

British journal of cancer, 2010-12, Vol.103 (12), p.1783-1787 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
9
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

CAMIDGE, D. Ross ; HERBST, Roy S ; BRAY, Gordon ; MENDELSON, David ; GORDON, Michael S ; GAIL ECKHARDT, S ; KURZROCK, Razelle ; DURBIN, Blythe ; ING, Josephine ; TOHNYA, Tanyifor M ; SAGER, Jason ; ASHKENAZI, Avi

Clinical cancer research, 2010-02, Vol.16 (4), p.1256-1263 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
10
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

TRARBACH, T ; MOEHLER, M ; HEINEMANN, V ; KÖHNE, C.-H ; PRZYBOREK, M ; SCHULZ, C ; SNELLER, V ; GALLANT, G ; KANZLER, S

British journal of cancer, 2010-02, Vol.102 (3), p.506-512 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (54)
  2. Revistas revisadas por pares (58)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (59)
  2. Book Chapters  (1)
  3. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2005  (5)
  2. 2005Até2007  (7)
  3. 2008Até2010  (17)
  4. 2011Até2014  (19)
  5. Após 2014  (12)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.